Investor
CAXTON CORP
CIK 0001388551 · filed 2026-05-14 · SEC filing
13F book
$4.02M
Positions
7
1 new · 5 sold
Largest name
81.5%
Spdr Gold Tr
Est. mark
$138.5K
Price effect on 6 names still held. Flow −$393.4K.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Spdr Gold Tr | — | 7.62K | $3.28M | 81.5% | $236.5K | Added$520K |
| Berkshire Hathaway Inc Del | — | 727 | $348.3K | 8.7% | −$16.6K | Added−$8.43K |
| Kyverna Therapeutics, Inc. | KYTX | 18.8K | $162K | 4.0% | −$14.5K | Held |
| Lexeo Therapeutics, Inc. | LXEO | 13.9K | $80K | 2.0% | −$58.4K | Held |
| X4 Pharmaceuticals, Inc | XFOR | 15.6K | $64.2K | 1.6% | $2.02K | Held |
| Inhibikase Therapeutics, Inc. | IKT | 28.5K | $47.8K | 1.2% | −$10.5K | Held |
| Alx Oncology Hldgs Inc | — | 20.9K | $42K | 1.0% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.